-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED AND INNOVENT JOINTLY ANNOUNCE NMPA APPROVAL FOR ELUNATE® (FRUQUINTINIB) IN COMBINATION WITH TYVYT® (SINTILIMAB INJECTION) FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Reuters·05/21/2026 10:00:25

Please log in to view news